Combination therapy with oncolytic viruses and immune checkpoint inhibitors

References

• Decker WK, da Silva RF, Sanabria MH, et al. Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol. 2017;8:829.
   PubMed Web of Science ®Google Scholar
• The Nobel Prize in Physiology or Medicine. 2018. Available from: https://www.nobelprize.org/prizes/medicine/2018/press-release/
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–167.
   PubMed Web of Science ®Google Scholar
• Haslam A, Prasad V. Estimation of the percentage of us patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Network Open. 2019;2(5):e192535–e.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350.
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3(9):e955691.
   PubMed Web of Science ®Google Scholar
• Pearl TM, Markert JM, Cassady KA, et al. Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors. Mol Ther Oncolytics. 2019;13:14–21.
   PubMed Web of Science ®Google Scholar
• Fountzilas C, Patel S, Mahalingam D. Review: oncolytic virotherapy, updates and future directions. Oncotarget. 2017;8:60.
   Google Scholar
• Trujillo JA, Sweis RF, Bao R, et al. T cell–inflamed versus non-t cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection. Cancer Immunol Res. 2018;6(9):990–1000.
   PubMed Web of Science ®Google Scholar
• Edelman DC. Human herpesvirus 8–a novel human pathogen. Virol J. 2005;2:78.
   PubMed Web of Science ®Google Scholar
• Chen CY, Hutzen B, Wedekind MF, et al. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother. 2018;7:65–77.
   PubMed Web of Science ®Google Scholar
• Du W, Seah I, Bougazzoul O, et al. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci U S A. 2017;114(30):E6157–E65.
   PubMed Web of Science ®Google Scholar
• Saha D, Martuza RL, Rabkin SD. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell. 2017;32(2):253–67 e5.
   PubMed Web of Science ®Google Scholar
• Wirsching HG, Zhang H, Szulzewsky F, et al. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. JCI Insight. 2019;4(13):e128217.
   PubMed Web of Science ®Google Scholar
• Sutherland CL, Rabinovich B, Chalupny NJ, et al. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood. 2006;108(4):1313–1319.
   PubMed Web of Science ®Google Scholar
• Passaro C, Alayo Q, De Laura I, et al. Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. Clin Cancer Res. 2019;25(1):290–299.
   PubMed Web of Science ®Google Scholar
• Thomas S, Kuncheria L, Roulstone V, et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer. 2019;7(1):214.
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303.
   PubMed Web of Science ®Google Scholar
• Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22(5):1048–1054.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Collichio FA, Amatruda T, et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2013;31(18_suppl):LBA9008–LBA.
   Web of Science ®Google Scholar
• Andtbacka RHI, Collichio F, Harrington KJ, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019;7(1):145.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718–730.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem MM, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619–2626.
   PubMed Web of Science ®Google Scholar
• Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase ii study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658–1667.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral t cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–19e10.
   PubMed Web of Science ®Google Scholar
• Eissa IR, Naoe Y, Bustos-Villalobos I, et al. Genomic signature of the natural oncolytic herpes simplex virus hf10 and its therapeutic role in preclinical and clinical trials. Front Oncol. 2017;7(149).
   Google Scholar
• Nakayama T, Yamashita M, Suzuki T, et al. Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without ipilimumab (Ipi) for advanced solid tumor patients (pts). J Clin Oncol. 2019;37(15_suppl):2610.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Ross MI, Agarwala SS, et al. Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma. J Clin Oncol. 2017;35(15_suppl):9510.
   Google Scholar
• Guo ZS, Lu B, Guo Z, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7(1):6.
   PubMedGoogle Scholar
• Thorne SH. Immunotherapeutic potential of oncolytic vaccinia virus. Front Oncol. 2014;4:155.
   PubMedGoogle Scholar
• Haddad D. Genetically engineered vaccinia viruses as agents for cancer treatment, imaging, and transgene delivery. Front Oncol. 2017;7:96.
   PubMed Web of Science ®Google Scholar
• Kleinpeter P, Fend L, Thioudellet C, et al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death −1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology. 2016;5(10):e1220467.
   PubMed Web of Science ®Google Scholar
• Kowalsky SJ, Liu Z, Feist M, et al. Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with pd-1 blockade. Mol Ther. 2018;26(10):2476–2486.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ravindranathan R, Kalinski P, et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754.
   PubMed Web of Science ®Google Scholar
• Budagian V, Bulanova E, Paus R, et al. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006;17(4):259–280.
   PubMed Web of Science ®Google Scholar
• Kinter AL, Godbout EJ, McNally JP, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181(10):6738–6746.
   PubMed Web of Science ®Google Scholar
• Smith HG, Mansfield D, Roulstone V, et al. PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma. Clin Cancer Res. 2019;25(11):3443–3454.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yu YA, Wang E, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007;67(20):10038–10046.
   PubMed Web of Science ®Google Scholar
• Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170(3):1257–1266.
   PubMed Web of Science ®Google Scholar
• Fend L, Yamazaki T, Remy C, et al. Immune checkpoint blockade, immunogenic chemotherapy or IFN-alpha blockade boost the local and abscopal effects of oncolytic virotherapy. Cancer Res. 2017;77(15):4146–4157.
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Sampath P, Hou W, et al. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res. 2015;21(24):5543–5551.
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Bell JC, Hwang TH, et al. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594). Oncolytic Virother. 2015;4:25–31.
   PubMed Web of Science ®Google Scholar
• Samson A, West E, Turnbull S, et al. 1213PSingle intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumour immunity. Ann Oncol. 2019;30(Supplement_5):v496.
   PubMedGoogle Scholar
• Chon H, Kim C. Abstract 5637: combination of oncolytic vaccinia virus and immune checkpoint blockade overcomes resistance to immunotherapy in renal cell carcinoma. Cancer Res. 2018;78(13 Supplement):5637.
   Web of Science ®Google Scholar
• Alemany R. Oncolytic adenoviruses in cancer treatment. Biomedicines. 2014;2(1):36–49.
   PubMedGoogle Scholar
• Buijs PR, Verhagen JH, van Eijck CH. van den Hoogen BG. Oncolytic viruses: from bench to bedside with a focus on safety. Hum Vaccin Immunother. 2015;11(7):1573–1584.
   PubMed Web of Science ®Google Scholar
• Niemann J, Kühnel F. Oncolytic viruses: adenoviruses. Virus Genes. 2017;53(5):700–706.
   PubMed Web of Science ®Google Scholar
• Cervera-Carrascon V, Siurala M, Santos JM, et al. TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology. 2018;7(5):e1412902.
   PubMed Web of Science ®Google Scholar
• Siurala M, Havunen R, Saha D, et al. Adenoviral delivery of tumor necrosis factor-alpha and interleukin-2 enables successful adoptive cell therapy of immunosuppressive melanoma. Mol Ther. 2016;24(8):1435–1443.
   PubMed Web of Science ®Google Scholar
• Speranza MC, Passaro C, Ricklefs F, et al. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 2018;20(2):225–235.
   PubMed Web of Science ®Google Scholar
• Jiang H, Rivera-Molina Y, Gomez-Manzano C, et al. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res. 2017;77(14):3894–3907.
   PubMed Web of Science ®Google Scholar
• Singh M, Vianden C, Cantwell MJ, et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017;8(1):1447.
   PubMed Web of Science ®Google Scholar
• Shin SP, Seo HH, Shin JH, et al. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. Mol Ther. 2013;21(3):688–695.
   PubMed Web of Science ®Google Scholar
• Tanoue K, Rosewell Shaw A, Watanabe N, et al. Armed oncolytic adenovirus-expressing pd-l1 mini-body enhances antitumor effects of chimeric antigen receptor t cells in solid tumors. Cancer Res. 2017;77(8):2040–2051.
   PubMed Web of Science ®Google Scholar
• McGray AJ, Bernard D, Hallett R, et al. Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology. 2012;1(4):419–431.
   PubMed Web of Science ®Google Scholar
• Cappuccini F, Stribbling S, Pollock E, et al. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother. 2016;65(6):701–713.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419–1427.
   PubMed Web of Science ®Google Scholar
• Zadeh G, Lang F, Daras M, et al. ATIM-24. Interim results of a Phase II multicenter study of the conditionally replicative oncolytic adenovirus DNX-2401 with pembrolizumab (Keytruda) for recurrent glioblastoma; captive study (Keynote-192). Neuro Oncol. 2018;20(suppl_6):vi6–vi.
   Google Scholar
• Cerullo V, Vaha-Koskela M, Hemminki A. Oncolytic adenoviruses: A potent form of tumor immunovirotherapy. Oncoimmunology. 2012;1(6):979–981.
   PubMed Web of Science ®Google Scholar
• Kuryk L, Moller AW, Jaderberg M. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2019;8(2):e1532763.
   PubMed Web of Science ®Google Scholar
• Kuryk L, Moller AW, Jaderberg M. Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma. J Med Virol. 2019;91(9):1702–1706.
   PubMed Web of Science ®Google Scholar
• Ranki T, Pesonen S, Hemminki A, et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016;4:17.
   PubMed Web of Science ®Google Scholar
• Kuhn I, Harden P, Bauzon M, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. Plos One. 2008;3(6):e2409.
   PubMed Web of Science ®Google Scholar
• Dyer A, Di Y, Calderon H, et al. Oncolytic group B adenovirus enadenotucirev mediates non-apoptotic cell death with membrane disruption and release of inflammatory mediators. Mol Ther Oncolytics. 2016;4:18–30.
   PubMed Web of Science ®Google Scholar
• Marino N, Illingworth S, Kodialbail P, et al. Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. Plos One. 2017;12(5):e0177810.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Salazar R, Duran I, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer. 2017;5(1):71.
   PubMedGoogle Scholar
• Machiels J-P, Salazar R, Rottey S, et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). J Immunother Cancer. 2019;7(1):20.
   PubMedGoogle Scholar
• Fakih MG, Wang D, Harb W, et al. 612PSPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase. Ann Oncol. 2019;30(Supplement_5).
   PubMedGoogle Scholar
• Bartee E, Bartee MY, Bogen B, et al. Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. Mol Ther Oncolytics. 2016;3:16032.
   PubMed Web of Science ®Google Scholar
• Burton C, Das A, McDonald D, et al. Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme. Oncolytic Virother. 2018;7:107–116.
   PubMed Web of Science ®Google Scholar
• Bartee MY, Dunlap KM, Bartee E. Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy. Cancer Res. 2017;77(11):2952–2963.
   PubMed Web of Science ®Google Scholar
• Bartee MY, Dryja PC, Bartee E. Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. J Immunother Cancer. 2019;7(1):11.
   PubMedGoogle Scholar
• Gong J, Sachdev E, Mita AC, et al. Clinical development of reovirus for cancer therapy: an oncolytic virus with immune-mediated antitumor activity. World J Methodol. 2016;6(1):25–42.
   PubMedGoogle Scholar
• Rajani K, Parrish C, Kottke T, et al. Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther. 2016;24(1):166–174.
   PubMed Web of Science ®Google Scholar
• Mostafa AA, Meyers DE, Thirukkumaran CM, et al. Oncolytic reovirus and immune checkpoint inhibition as a novel immunotherapeutic strategy for breast cancer. Cancers (Basel). 2018;10(6):205.
   PubMed Web of Science ®Google Scholar
• Kelly KR, Espitia CM, Zhao W, et al. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia. 2018;32(1):230–233.
   PubMed Web of Science ®Google Scholar
• Ilett E, Kottke T, Thompson J, et al. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene Ther. 2017;24(1):21–30.
   PubMed Web of Science ®Google Scholar
• Samson A, Scott KJ, Taggart D, et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med. 2018;10(422):eaam7577.
   PubMed Web of Science ®Google Scholar
• Lolkema MP, Arkenau HT, Harrington K, et al. A phase I study of the combination of intravenous reovirus type 3 dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res. 2011;17(3):581–588.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Goel S, Aparo S, et al. A phase II study of pelareorep (REOLYSIN(®)) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma. Cancers (Basel). 2018;10(6):160.
   PubMed Web of Science ®Google Scholar
• Fountzilas C, Wilkinson GA, Eng KH, et al. Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2019;37(15_suppl):e15726–e.
   Web of Science ®Google Scholar
• Organisation WH. Immunization, vaccines and biologicals – rotavirus. Available from: https://www.who.int/immunization/diseases/rotavirus/en/.
   Google Scholar
• Pesavento JBCS, Estes MK, Prasad BV. Rotavirus proteins: structure and assembly. Reoviruses: entry, assembly and morphogenesis current topics in microbiology and immunology. Berlin, Heidelberg: Springer-Verlag. 2006. p. 189–219.
   Google Scholar
• Shekarian T, Sivado E, Jallas AC, et al. Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. Sci Transl Med. 2019;11(515):eaat5025.
   PubMed Web of Science ®Google Scholar
• Stanway G. Structure, function and evolution of picornaviruses. J Gen Virol. 1990;71(Pt 11):2483–2501.
   PubMedGoogle Scholar
• Bradley S, Jakes AD, Harrington K, et al. Applications of coxsackievirus A21 in oncology. Oncolytic Virother. 2014;3:47–55.
   PubMedGoogle Scholar
• Shafren DR, Dorahy DJ, Ingham RA, et al. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol. 1997;71(6):4736–4743.
   PubMed Web of Science ®Google Scholar
• Reina M, Espel E. Role of LFA-1 and ICAM-1 in cancer. Cancers (Basel). 2017;9(11):153.
   PubMed Web of Science ®Google Scholar
• Annels NE, Arif M, Simpson GR, et al. Oncolytic immunotherapy for bladder cancer using coxsackie A21 virus. Mol Ther Oncolytics. 2018;9:1–12.
   PubMed Web of Science ®Google Scholar
• Shafren D, Quah M, Wong Y, et al. 1066 Pcombination of a novel oncolytic immunotherapeutic agent, coxsackievirus a21 and pd-1 blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model. Ann Oncol. 2014;25(suppl_4):iv367–iv8.
   Google Scholar
• Pandha H, editor Clinical evaluation of a novel oncolytic immunotherapy agent, CAVATAK® in combination with immune checkpoint therapy in advanced cancer patients International Oncolytic Virus Conference, Oxford, UK; 2018.
   Google Scholar
• Louten J. Essential human virology, chapter 14 - poliovirus. Elsevier Inc. 2016.
   Google Scholar
• Organisation WH. Available from: https://www.who.int/news-room/fact-sheets/detail/poliomyelitis.
   Google Scholar
• Gromeier M, Nair SK. Recombinant poliovirus for cancer immunotherapy. Annu Rev Med. 2018;69:289–299.
   PubMed Web of Science ®Google Scholar
• Force J, Holl E, Brown M, et al. Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy. J Clin Oncol. 2018;36(15_suppl):e12641–e.
   Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150–161.
   PubMed Web of Science ®Google Scholar
• James H, Strauss EGS. Minus-strand RNA viruses. In: James H, Strauss EGS, editors. Viruses and human disease. Second ed. Elsevier Inc. 2008. p. 137–191.
   Google Scholar
• Fine SM. Vesicular stomatitis virus and related vesiculoviruses. In: John E, Bennett RD, Martin J, et al., editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8 ed. Elsevier Inc. 2015. p. 1981–1983.
   Google Scholar
• Suder E, Furuyama W, Feldmann H, et al. The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials. Hum Vaccin Immunother. 2018;14(9):2107–2113.
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4(4):263–275.
   PubMed Web of Science ®Google Scholar
• Shen W, Patnaik MM, Ruiz A, et al. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood. 2016;127(11):1449–1458.
   PubMed Web of Science ®Google Scholar
• Cockle JV, Rajani K, Zaidi S, et al. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol. 2016;18(4):518–527.
   PubMed Web of Science ®Google Scholar
• Brun J, McManus D, Lefebvre C, et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther. 2010;18(8):1440–1449.
   PubMed Web of Science ®Google Scholar
• Bourgeois-Daigneault M-C, Roy DG, Aitken AS, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018;10(422):eaao1641.
   PubMed Web of Science ®Google Scholar
• Pol JG, Acuna SA, Yadollahi B, et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2019;8(1):e1512329.
   PubMed Web of Science ®Google Scholar
• Atherton MJ, Stephenson KB, Pol J, et al. Customized viral immunotherapy for HPV-associated cancer. Cancer Immunol Res. 2017;5(10):847–859.
   PubMed Web of Science ®Google Scholar
• Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007;98(10):1505–1511.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Yadava PK. Measles virus: background and oncolytic virotherapy. Biochem Biophys Rep. 2018;13:58–62.
   PubMedGoogle Scholar
• Immunization, vaccines and biologicals - measles. Available from: https://www.who.int/immunization/diseases/measles/en/.
   Google Scholar
• Msaouel P, Iankov ID, Dispenzieri A, et al. Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol. 2012;13(9):1732–1741.
   PubMed Web of Science ®Google Scholar
• Hardcastle J, Mills L, Malo CS, et al. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol. 2017;19(4):493–502.
   PubMed Web of Science ®Google Scholar
• Engeland CE, Grossardt C, Veinalde R, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther. 2014;22(11):1949–1959.
   PubMed Web of Science ®Google Scholar
• David H, Holman DW, Woraratanadharm J, et al. Viral vectors. In: Alan DT, Barrett LRS, editors. Vaccines for biodefense and emerging and neglected diseases. Elsevier Inc. 2009. p. 77–91.
   Google Scholar
• Schirrmacher V, van Gool S, Stuecker W. Breaking therapy resistance: an update on oncolytic newcastle disease virus for improvements of cancer therapy. Biomedicines. 2019;7(3):66.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6(226):226ra32.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Holmgaard RB, Ricca J, et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017;8:14340.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Ricca JM, Sadekova S, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128(4):1413–1428.
   PubMed Web of Science ®Google Scholar
• Schmaljohn AL, McClainD. Alphaviruses (Togaviridae) and Flaviviruses (Flaviviridae). In: Baron S, editors. Medical microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston. 1996. Available from: https://www.ncbi.nlm.nih.gov/books/NBK7633/
   Google Scholar
• Lundstrom K. Oncolytic Alphaviruses in Cancer Immunotherapy. Vaccines (Basel). 2017;5(2):9.
   PubMed Web of Science ®Google Scholar
• Scherwitzl I, Hurtado A, Pierce CM, et al. Systemically administered sindbis virus in combination with immune checkpoint blockade induces curative anti-tumor immunity. Mol Ther Oncolytics. 2018;9:51–63.
   PubMed Web of Science ®Google Scholar
• Quetglas JI, Labiano S, Aznar MÁ, et al. Virotherapy with a Semliki forest virus–based vector encoding IL12 synergizes with PD-1/PD-L1 blockade. Cancer Immunol Res. 2015;3(5):449–454.
   PubMed Web of Science ®Google Scholar
• Ballesteros-Briones MC, Martisova E, Casales E, et al. Short-term local expression of a PD-L1 blocking antibody from a self-replicating RNA vector induces potent antitumor responses. Mol Ther. 2019;27:1892–1905.
   PubMedGoogle Scholar
• Parker JN, Meleth S, Hughes KB, et al. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 2005;12(4):359–368.
   PubMed Web of Science ®Google Scholar
• Li J, O’Malley M, Urban J, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther. 2011;19(4):650–657.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ravindranathan R, Li J, et al. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology. 2016;5(3):e1091554.
   PubMed Web of Science ®Google Scholar
• Francis L, Guo ZS, Liu Z, et al. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget. 2016;7(16):22174–22185.
   PubMedGoogle Scholar
• Quetglas JI, Dubrot J, Bezunartea J, et al. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki forest virus encoding IL-12. Mol Ther. 2012;20(9):1664–1675.
   PubMed Web of Science ®Google Scholar
• Yu M, Scherwitzl I, Opp S, et al. Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody. J Immunother Cancer. 2019;7(1):185.
   PubMedGoogle Scholar
• John LB, Howland LJ, Flynn JK, et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res. 2012;72(7):1651–1660.
   PubMed Web of Science ®Google Scholar
• Kim H, Kim-Schulze S, Kim D, et al. Host lymphodepletion enhances the therapeutic activity of an oncolytic Vaccinia virus expressing 4-1BB Ligand. Cancer Res. 2009;69:8516–8525.
   PubMed Web of Science ®Google Scholar
• Huang JH, Zhang SN, Choi KJ, et al. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther. 2010;18(2):264–274.
   PubMed Web of Science ®Google Scholar
• Pesonen S, Diaconu I, Kangasniemi L, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012;72(7):1621–1631.
   PubMed Web of Science ®Google Scholar
• Durham NM, Mulgrew K, McGlinchey K, et al. Oncolytic VSV primes differential responses to immuno-oncology therapy. Mol Ther. 2017;25(8):1917–1932.
   PubMed Web of Science ®Google Scholar
• Andarini S, Kikuchi T, Nukiwa M, et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 2004;64(9):3281–3287.
   PubMed Web of Science ®Google Scholar
• Martinez FWP, Rivera YA, Nguyen T, et al. Abstract 3668: oncolytic adenoviruses expressing OX40L or GITRL immune modulators show antitumor effect on immune-competent mouse breast cancer models. Cancer Res. 2017;77(13 Supplement):3668.
   Google Scholar
• Rivera-Molina Y, Jiang H, Fueyo J, et al. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. Neurooncol Adv. 2019;1(1):vdz009.
   PubMedGoogle Scholar
• Aida K, Miyakawa R, Suzuki K, et al. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-alpha gene therapy for pancreatic cancer. Cancer Sci. 2014;105(2):159–167.
   PubMed Web of Science ®Google Scholar
• Calmels B, Paul S, Futin N, et al. Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther. 2005;12(2):198–205.
   PubMed Web of Science ®Google Scholar
• Freedman JD, Hagel J, Scott EM, et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med. 2017;9(8):1067–1087.
   PubMed Web of Science ®Google Scholar
• Speck T, Heidbuechel JPW, Veinalde R, et al. Targeted biTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors. Clin Cancer Res. 2018;24(9):2128–2137.
   PubMed Web of Science ®Google Scholar
• Fajardo CA, Guedan S, Rojas LA, et al. Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Cancer Res. 2017;77(8):2052–2063.
   PubMed Web of Science ®Google Scholar
• Yu F, Wang X, Guo ZS, et al. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther. 2014;22(1):102–111.
   PubMed Web of Science ®Google Scholar
• Freedman JD, Duffy MR, Lei-Rossmann J, et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res. 2018;78(24):6852–6865.
   PubMed Web of Science ®Google Scholar
• Rosewell Shaw A, Porter CE, Watanabe N, et al. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer. Mol Ther. 2017;25(11):2440–2451.
   PubMed Web of Science ®Google Scholar
• Wing A, Fajardo CA, Posey AD Jr., et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018;6(5):605–616.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Luo Y, Da T, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018;3(7):e99573.
   Web of Science ®Google Scholar
• Nishio N, Diaconu I, Liu H, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014;74(18):5195–5205.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439–448.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Rosewell Shaw A, Suzuki M. Oncolytic viruses partner with T-cell therapy for solid tumor treatment. Front Immunol. 2018;9:2103.
   PubMed Web of Science ®Google Scholar
• Ajina A, Maher J. Prospects for combined use of oncolytic viruses and CAR T-cells. J Immunother Cancer. 2017;5(1):90.
   PubMedGoogle Scholar
• de Graaf JF, de Vor L, Fouchier RAM. van den Hoogen BG. Armed oncolytic viruses: A kick-start for anti-tumor immunity. Cytokine Growth Factor Rev. 2018;41:28–39.
   PubMed Web of Science ®Google Scholar
• de Gruijl TD, Janssen AB, van Beusechem VW. Arming oncolytic viruses to leverage antitumor immunity. Expert Opin Biol Ther. 2015;15(7):959–971.
   PubMed Web of Science ®Google Scholar
• Scott EM, Duffy MR, Freedman JD, et al. Solid Tumor Immunotherapy with T cell engager-armed oncolytic viruses. Macromol Biosci. 2018;18(1):1700187.
   PubMed Web of Science ®Google Scholar
• Harrington K, Freeman DJ, Kelly B, et al. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18(9):689–706.
   PubMed Web of Science ®Google Scholar